Skye Bioscience, Inc. (SKYE) - Long-Term Debt to Capital

Skye Bioscience, Inc. (SKYE) is integrating ESG principles into the development of cannabinoid products by minimizing environmental impact during procurement. The company is expanding its pipeline of treatments for obesity and glaucoma under the strict supervision of the FDA and DEA. This chart of share prices captures the 0.00 metric. The business is automating substance synthesis using algorithms, although final medical oversight remains with specialists.

Low long-term leverage minimizes bankruptcy risk during external shocks, which is critical for Skye Bioscience, Inc. (SKYE), as its net margin is temporarily constrained by high clinical trial costs. The ratio of loans with maturities exceeding one year to equity, reflected in the long-term debt-to-equity structure, allows investors to assess the company's financial autonomy and its ability to fund R&D without excessive debt burden.